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Dabigatran Compared with Warfarin for Stroke 
Prevention in Patients with Atrial Fibrillation:
An Evidence Based Case Report
Alvin Nursalim*, Yoga Yuniadi**
Background. Atrial fibrillation (AF) increases the risk of having stroke as 
high as five fold. Anticoagulant administration such as vitamin K antagonist 
has been used regularly to reduce the occurence of stroke. Despite the 
high  efficacy, warfarin has several limitations, including a narrow therapeutic 
window, multiple food and drug interactions, and the need for frequent 
laboratory monitoring. Dabigatran, an oral thrombin inhibitor, displays some 
positive characteristics as the solution to warfarin’s limitations.
Aim. To determine the efficacy of dabigatran compared to warfarin for 
stroke prevention in patients with atrial fibrillation.
Methods. A search was conducted on PubMed and Google. The selection 
of title and abstract was done using inclusion and exclusion criteria. Five 
original articles were found, but only one study was used. The selected 
study was critically appraised for its validity, importance and applicability.
Result. The administration of 150 mg of dabigatran was superior to 
warfarin with respect of stroke. The relative risk reduction was 36% in 
the 150 mg dabigatran group. The rate of stroke was 1.01% per year in 
the group that received 150 mg dabigatran, as compared with 1.57% per 
year in the warfarin group (relative risk 0.64; 95% confidence interval, 0.51 
to 0.81, p<0.001). The administration of dabigatran increased the risk of 
gastrointestinal bleeding.
Conclusion. In patients with atrial fibrillation, dabigatran given at a dose 
of 150 mg, as compared with warfarin, was associated with lower rate 
of stroke. Dabigatran administration requires closed gastrointestinal 
monitoring.
(J Kardiol Indones. 2011;32:249-54)
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Laporan Kasus
Clinical Scenario
Sixty five years old man was admitted to the hospital 
with palpitation since three days before hospital 
admission. The patient denied the same complaint 
before and had history of heart failure. The patient 
denied any history of chest pain, diabetes mellitus 
and gastrointestinal disease. From the physical 
examination BP: 150/90, temperature: 37oC, HR: 
Latar belakang. Atrial fibrilasi (AF) meningkatkan risiko terjadinya stroke sebanyak lima kali. Warfarin, golongan antagonist 
vitamin K, telah digunakan cukup lama untuk menurunkan kejadian stroke. Namun warfarin memiliki beberapa keterbatasan 
seperti ambang terapi yang sempit, berbagai interaksi obat dan diperlukannya pemantauan berkala. Dabigatran, antitrombin 
oral, memiliki beberapa keunggulan sebagai jawaban sebagai keterbatasan dari warfarin.
Tujuan. Menentukan efektivitas dabigatran dibandingkan warfarin untuk pencegahan stroke pada pasien dengan atrial 
fibrillasi.
Metode. Pencarian terstruktur dilakukan dengan menggunakan Pubmed dan Google. Setelah dilakukan penapisan judul dan 
abstrak dengan kriteria inklusi dan eksklusi, lima studi ditemukan, tetapi hanya satu studi yang digunakan penulis. Studi 
ini ditelaah dengan menggunakan kriteria yang mencakup validity, importance, dan applicability untuk menentukan derajat 
kegunaan dalam studi ini.
Hasil. Pemberian dabigatran sebanyak 150 mg menyebabkan penurunan risiko terjadinya komplikasi stroke pada pasien AF 
sebesar 36% dibandingkan warfarin. Kejadian stroke pada kelompok yang menerima 150 mg dabigatran sebesar 1.01% per 
tahun dibandingkan dengan 1.57% pada kelompok warfarin. (relative risk 0.64; 95% confidence interval, 0.51­0.81, p<0.001). 
Namun pemberian dabigatran meningkatkan risiko terjadinya perdarahan gatrointestinal.
Kesimpulan. Pemberian 150 mg dabigatran menurunkan risiko terjadinya stroke pada pasien AF dibandingkan pemberian 
warfarin. Namun pemberian dabigatran memerlukan pemantaun perdarahan gastrointestinal.
(J Kardiol Indones. 2011;32:249­54)
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irreguler. RR: 30x. There was no abnormality 
found in other physical examination. The doctor 
suspected the patient had atrial fibrillation which 
then confirmed by electrocardiography examination. 
The CHADS2 score of this patient is two due to 
congestive heart failure and hypertension. After 
the administration of regular prescription for atrial 
fibrillation, the doctor faced a dilemmatic choice for 
the anticoagulant whether to administer warfarin, 
the popular drug he had been using for years or 
dabigatran, a new drug he just knew.
Introduction
Atrial fibrillation (AF) is the most common cardiac 
rhytm disorder and a powerful risk factor for stroke, 
independently increasing risk five­fold throughout 
all ages. The percentage of strokes attributable to AF 
increases steeply from 1.5% at 50 to 59 years of age 
to 23.5% at 80 to 89 years of age.1
Currently, Vitamin K antagonists (VKA) are 
commonly used to prevent stroke in AF patients. Until 
recently, VKA are the only orally active anticoagulants 
available. Warfarin, the most commonly used oral 
VKA, reduces the risk of stroke in patients with 
nonvalvular AF by 68%. Despite the high efficacy, 
warfarin has several limitations, including a narrow 
therapeutic window, multiple food and drug 
interactions, and the need for frequent laboratory 
monitoring. Due to its limitations, the therapeutic 
range is achieved in less than two­thirds of patients 
in clinical practice.2 An orally effective anticoagulant, 
with less drug interaction and without the need for 
regular monitoring would be the answer to warfarin’s 
limitations.
Dabigatran etexilate is an orally available 
prodrug that is converted to dabigatran, the active 
substrate. It is a reversible direct inhibitor of 
thrombin. Its half­life (T1/2) is 14–17 hours and is 
excreted out through kidneys; thus, once or twice 
daily administration is enough.3 Dabigatran has a 
rapid onset of action and does not need frequent 
monitoring.4 Dabigatran does displays some positive 
characteristics, but whether its efficacy is equal 
or even better than warfarin need to be further 
investigated. This report is made to identify the 
efficacy of dabigatran compared to warfarin for 
stroke prevention in atrial fibrillation patients.
Clinical Question
Is dabigatran as effective as warfarin for stroke 
prevention in patients with atrial fibrillation?
Methods
Search strategy
PubMed,® and Google,® search was performed on 
November 2nd and 3rd  2011, using the keywords 
“dabigatran”, “warfarin”, “stroke” and “atrial 
fibrillation”along with its synonyms and related terms 
(Table 1). Searchstrategy, results, the inclusion and 
exclusion criteria are shown in a flowchart (Figure 
1).
Selection
The first selection was based on title and abstract 
using inclusion  criterias and exclusion criteria.. After 
selection, filtration and screening title abstract, one 
full­text article was available.
Table 1.Search strategy used in PubMed and Google (Conducted on November 2nd and 3rd 2011)
Database Search terms Results
Pubmed 
(2nd November 2011)
“dabigatran”[All Fields]) AND (“warfarin”[MeSH Terms] 
OR “warfarin”[All Fields]) AND (“stroke”[MeSH Terms] OR 
“stroke”[All Fields]) AND (“atrial fibrillation”[MeSH Terms] 
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Result
The study conducted by Connolly SJ et al5 is a phase 
III trial on 18,113 patients from 951 clinical centers in 
44 countries. The study was a prospective, randomized, 
open­label, blinded­endpoint trial. Connolly SJ et al 
Critical Appraisal
After the selection, critical appraisal was done using 
several aspects based on Center of Evidence­based 
Medicine, University of Oxford  for therapy study 
(Table 2).
Figure 1. Flow Chart of Search Strategy
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conducted a study to determine the efficacy of 110 
mg and 150 mg of dabigatran compared to warfarin. 
Warfarin is given in tablets of 1, 3 or 5 mg and was 
adjusted locally to an international normalized ratio 
(INR) of 2.0­3.0.
In the first group, 110 mg of dabigatran is given 
to 6015 patients with atrial fibrillation. After a mean 
of 2 years follow­up, stroke occured in 171 patients 
receiving 110 mg of dabigatran compared to 185 
patients in the warfarin group.The Control Event 
Rate (CER) was 3.1%, Experimental Event Rate 
(EER) was 2.8%, Relative Risk Reduction (RRR) 
was 9.7%, Absolute Risk Reduction (ARR) was 0.3% 
and Number Needed to Treat (NNT) was 333.The 
outcome of stroke was 1.44% per year in the 110 mg 
group, as compared with 1.57% in the warfarin group 
(relative risk 0.92; 95% confidence interval, 0.74 to 
1.13). The meassurement of primary outcome in this 
tudy which include systemic embolism stated that  the 
rates of primary outcome were 1.53% in the 110 mg of 
dabigatran and 1.69% in the warfarin group (relative 
risk 0.91; 95% confidence interval, 0.74­1.11)
In the second group, 150 mg of dabigatran is 
given to  6076 patients with atrial fibrillation. The 
outcome of stroke occured in 122 patients receiving 
150 mg of dabigatran compared to 185 patients in 
the warfarin group. The CER was 3.1%, EER was 
2%, RRR was 36%, ARR was 1.1%  and NNT was 
91. The outcome of stroke was 1.01% per year in the 
150 mg dabigatran group, as compared with 1.57% in 
the warfarin group (relative risk 0.64; 95% confidence 
interval, 0.51­0.81).
Discussion
Connolly et al5 conducted a study with 18,113 patients 
originated from 44 countries. This distribution 
can be a fair representative of race variability. The 
characteristics of the patients’ baseline similar to the 
patient’s age and gender presented in the clinical 
scenario. The mean age of patients in the 110 mg 
dabigatran, 150 mg dabigatran and warfarin group 
are 71.4± 8.6, 71.5±8.8 and 71.6±8.6 respectively. 
Table 2. Critical Appraisal of the usefull articles based on criterias by Centre of Evidence Medicine Uni­
versity of Oxford6





























































































Connolly SJ et al5 + 18,113 + + +/­** + + + + + A 1B
Legend:  + stated clearly in the article
 ­ not being done
 ? not stated clearly
*Levels of evidence based on The Oxford Centre of Evidence­based Medicine
**Dabigatran was administered in a blinded fashion, while warfarin was administered in an unblinded fashion
Domain: Patients’ mean age is 71 years old. Patients were eligible ifthey had atrial fibrillation documented on  
 electrocardiography performed at screening or within 6 months beforehand.
Determinant: Administration of 110 mg and 150 mg of dabigatran (twice daily) and warfarin
Outcome: The occurence of stroke and systemic embolism
A: The administration of 150 mg of dabigatran was superior to warfarin in reducing the occurence of disabling stroke. 
(relative risk: 0.66; 95% confidence interval, 0.53 to 0.82; P<0.001) . 
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Most of the patients participated in this study are man 
(64.3%, 63.2% and 63.3% respectively). The mean 
CHADS2 score was 2,1.
According to this study, the administration of 110 
mg of dabigatran was equal to warfarin in preventing 
the occurence of stroke. There was no significant 
reduction of stroke in the 110 mg dabigatran group. 
In terms of major bleeding, the administration of 110 
mg of dabigatran is associated with less major bleeding 
compared to warfarin.
The administration of 150 mg of dabigatran was 
superior to warfarin in the prevention of stroke. The 
relative risk reduction was 36%, the ARR  was 1.1 % 
and the NNT was 91. The high NNT was tolerable 
since it is a prophylactic interventions that produce 
small effects in large numbers of patients and associated 
with critical diseases. TheNNT in this study  can still 
be considered beneficial as a preventive meassure of 
stroke in AF patients.
The rate of life­threatening bleeding, intracranial 
bleeding and major or minor bleeding were higher with 
warfarin than with either the 110 mg or 150 mg dose 
of dabigatran. While the administration of 150 mg was 
associated with decreased risk of stroke and decreased 
risk of major bleeding, but the rate of gastrointestinal 
bleeding in this group increased. This phenomenon 
can be explained by the pharmakocinetics of dabigatran 
that requires low pH for it’s absorbtion. Therefore, 
dabigatran capsules contain dabigatran­coated pellets 
with a tartaric acid core. This acid core contributes 
to the increasing acidity and increased incidence of 
dyspeptic symptoms in patients taking this drug.
Conclusion and recommendation
The administration of 110 mg of dabigatran, as 
compared with warfarin, was associated with similar 
rates of stroke and and lower rates of major bleeding; 
the 150 mg dose of dabigatran was associated with 
lower rates of stroke but with a similar rate of major 
bleeding. The administration of dabigatran must 
be accompanied by each patient’s characteristic 
examnination, especially gastrointestinal disease. 
Since there was an increase of gastrointestinal 
bleeding with the increase of dabigatran dose, so 
gastrointestinal monitoring is recommended in all 
patients receiving dabigatran.This report can be 
translated into clinical practise. We recommend 
the administration of 150 mg for the patient in the 
clinical scenario above, with closed gastrointestinal 
monitoring.
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